[TABLE OF CONTENTS]

1 INTRODUCTION OF GLOBAL LIVER CANCER DIAGNOSTICS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES

4 GLOBAL LIVER CANCER DIAGNOSTICS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS

5 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE
5.1 OVERVIEW
5.2 LABORATORY TESTS
5.2.1 BIOMARKERS
5.2.1.1 ONCOFETAL AND GLYCOPROTEIN ANTIGENS
5.2.1.2 ENZYMES AND ISOENZYMES
5.2.1.3 GROWTH FACTORS AND RECEPTORS
5.2.1.4 MOLECULAR MARKERS
5.2.1.5 PATHOLOGICAL BIOMARKERS
5.2.2 BLOOD TESTS
5.3 IMAGING TESTS
5.4 ENDOSCOPY
5.5 BIOPSY
5.6 OTHERS

6 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY END-USE
6.1 OVERVIEW
6.2 HOSPITALS & DIAGNOSTIC LABORATORIES
6.3 ACADEMIC & RESEARCH INSTITUTES
6.4 PHARMACEUTICAL & CRO LABORATORIES

7 GLOBAL LIVER CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY
7.1 OVERVIEW

7.2 NORTH AMERICA

7.2.1 NORTH AMERICA MARKET SNAPSHOT
7.2.2 U.S.
7.2.3 CANADA
7.2.4 MEXICO

7.3 EUROPE

7.3.1 EUROPE MARKET SNAPSHOT
7.3.2 WESTERN EUROPE
7.3.2.1 THE UK
7.3.2.2 GERMANY
7.3.2.3 FRANCE
7.3.2.4 ITALY
7.3.2.5 SPAIN
7.3.2.6 REST OF WESTERN EUROPE
7.3.3 EASTERN EUROPE
7.3.3. 1 POLAND
7.3.3.2 RUSSIA
7.3.3.3 REST OF EASTERN EUROPE

7.4 ASIA PACIFIC

7.4.1 ASIA PACIFIC MARKET SNAPSHOT
7.4.2 CHINA
7.4.3 JAPAN
7.4.4 INDIA
7.4.5 AUSTRALIA & NEW ZEALAND
7.4.6 ASEAN
7.4.7 REST OF ASIA PACIFIC

7.5 MIDDLE EAST & AFRICA

7.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
7.5.2 UAE
7.5.3 SAUDI ARABIA
7.5.4 SOUTH AFRICA
7.5.5 REST OF MEA

7.6 SOUTH AMERICA

7.6.1 SOUTH AMERICA MARKET SNAPSHOT
7.6.2 BRAZIL
7.6.3 ARGENTINA
7.6.4 REST OF SOUTH AMERICA

8 GLOBAL LIVER CANCER DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE
8.1 OVERVIEW
8.2 COMPANY MARKET RANKING
8.3 KEY DEVELOPMENT STRATEGIES

9 COMPANY PROFILES

9.1 ABBOTT LABORATORIES
9.1.1 OVERVIEW
9.1.2 FINANCIAL PERFORMANCE
9.1.3 PRODUCT OUTLOOK
9.1.4 KEY DEVELOPMENTS

9.2 BECTON DICKINSON & COMPANY
9.2.1 OVERVIEW
9.2.2 FINANCIAL PERFORMANCE
9.2.3 PRODUCT OUTLOOK
9.2.4 KEY DEVELOPMENTS

9.3 EPIGENOMICS AG
9.3.1 OVERVIEW
9.3.2 FINANCIAL PERFORMANCE
9.3.3 PRODUCT OUTLOOK
9.3.4 KEY DEVELOPMENTS

9.4 F. HOFFMANN-LA ROCHE LTD.
9.4.1 OVERVIEW
9.4.2 FINANCIAL PERFORMANCE
9.4.3 PRODUCT OUTLOOK
9.4.4 KEY DEVELOPMENTS

9.5 FUJIFILM MEDICAL SYSTEMS U.S.A., INC.
9.5.1 OVERVIEW
9.5.2 FINANCIAL PERFORMANCE
9.5.3 PRODUCT OUTLOOK
9.5.4 KEY DEVELOPMENTS

9.6 ILLUMINA, INC.
9.6.1 OVERVIEW
9.6.2 FINANCIAL PERFORMANCE
9.6.3 PRODUCT OUTLOOK
9.6.4 KEY DEVELOPMENTS

9.7 KONINKLIJKE PHILIPS N.V.
9.7.1 OVERVIEW
9.7.2 FINANCIAL PERFORMANCE
9.7.3 PRODUCT OUTLOOK
9.7.4 KEY DEVELOPMENTS

9.8 QIAGEN N.V.
9.8.1 OVERVIEW
9.8.2 FINANCIAL PERFORMANCE
9.8.3 PRODUCT OUTLOOK
9.8.4 KEY DEVELOPMENTS

9.9 SIEMENS HEALTHINEERS
9.9.1 OVERVIEW
9.9.2 FINANCIAL PERFORMANCE
9.9.3 PRODUCT OUTLOOK
9.9.4 KEY DEVELOPMENTS

9.10 THERMO FISHER SCIENTIFIC, INC.
9.10.1 OVERVIEW
9.10.2 FINANCIAL PERFORMANCE
9.10.3 PRODUCT OUTLOOK
9.10.4 KEY DEVELOPMENTS